As of today, there are no formal, peer-reviewed human clinical trials that have studied the safety or efficacy of administering Retatrutide and CJC-1295 concurrently
Retatrutide (also designated LY3437943) is a synthetic, investigational-grade peptide engineered as a unimolecular triple agonist targeting three key metabolic receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GcgR)
[Google Scholar] 84.Desalermos A., Russell B., Leggett C., Parnell A., Ober K., Hagerich K., Gerlan C., Ganji G., Lee E., Proudfoot J.A., et al
Researchers have explored compounds in this class to better understand peptide receptor interactions and cellular signaling mechanisms
If a pharmacy uses unapproved ingredients like salt forms, there is no data on how they will affect the body, their potency, or potential side effects
What are Microdose GLP-1 benefits